In-vitro metabolism of anti-cancer drugs, methods and applications: Paclitaxel docetaxel, tamoxifen and ifosfamide

Cancer Treatment Reviews

Volumn 24, Issue 5, 1998, Pages 345-366

  Crommentuyn, K M L ^a   Schellens, J H M ^b   Van Den Berg, J D ^b   Beijnen, J H ^a,b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450; DOCETAXEL; IFOSFAMIDE; MONOCLONAL ANTIBODY; PACLITAXEL; POLYCLONAL ANTIBODY; TAMOXIFEN;

DRUG METABOLISM; ENZYME INDUCTION; ENZYME INHIBITION; EPITHELIUM CELL; LIVER CELL; LIVER CELL CULTURE; LIVER MICROSOME; REVIEW;

EID: 0031732997     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(98)90057-3     Document Type: Article

References (91)

1. Groothuis GMM. Aan het woord. TCCD 1996; 3: 30-32.
2. Rang HP, Dale MM & Ritter JM. Pharmacology 1995; Third edition. Churchill Livingstone, p. 83.
3. Birkett DJ, Mackenzie PJ, Veronese ME & Miners JO. In vitro approaches can predict human drug metabolism. TiPS 1993; 14: 292-294.
4. Gonzalez FJ. In vitro systems for prediction of rates of drug clearance and drug interactions. J. Anaesthesiology 1992; 77: 413-415.
5. Smith DA. Species differences in pharmacokinetics: are we close to an understanding? Drug Metab. Rev. 1991; 23: 355-373.
6. Slaughter RL & Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann. Pharmacother. 1995; 29: 619-624.
7. Gonzalez FJ. Human cytochromes P450: problems and prospects. TiPS 1992; 13: 346-352.
8. Wrighton SA & Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 1992; 22-1: 1-21.
9. Nebert DW, Adesnick M, Coon MJ, Estabook RW, Gonzalez FJ, Guengerich FP et al. The P450 gene superfamily: recommended nomenclature. DNA 1987; 6: 1-11.
10. Murray M. Mechanisms of the inhibition of cytochrome P450-mediated drug oxidation by therapeutic agents. Drug Metab. Rev. 1987; 18-1: 55-81.
11. Murray M. P450 enzymes: Inhibition mechanisms, genetic regulation and effects of liver disease. Clin. Pharmacokinet. 1992; 23-2: 132-146.
12. Cholerton S, Daly AK & Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. TiPS 1992; 13: 434-439.
13. Guengerich FP. Minireview: Human cytochrome P450 enzymes. Life Sci. 1992; 50: 1471-1487.
14. Nemeroff CB, De Vane CL & Pollock BG. Newer anti-depressants and the cytochrome P450 system. Am. J. Psychiatry 1996; 153-3: 311-320.
15. Danhoff M. Is drug metabolism predictable? P.W. 1996; 131: 1191-1192.
16. Smith DA & Jones BC. Commentary: Speculations on the structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem. Pharmacol. 1992; 44: 2089-2098.
17. Kivistö KT, Kroemer HK & Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions. Br. J. Clin. Pharmacol. 1995; 40: 523-530.
18. Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson ADJ, Beaune PH & Idle JR. Identification of the major hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem. Pharmacol. 1994; 47: 1157-1163.
19. Guengerich FP, Dannan GA, Wright ST & Marvin MV. Purification and characterization of microsomal cytochrome P450s. Xenobiotica 1982; 12: 701-716.
20. Schmider JG, Greenblatt MD, von Moltke LL & Shader RI. Editorial: Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: Implications or diazepam disposition in humans. J. Clin. Psychopharmacol. 1960; 16: 267-272.
21. Lee Chiu SH. The use of in vitro metabolism studies in the understanding of new drugs. J. Pharmacol. 1993; 29: 77-83.
22. Worboys PD, Bradbury A & Houston JB. Kinetics of drug metabolism in rat liver slices. Comparison of clearance by liver slices and freshly isolated hepatocytes. Drug Metab. Rev. 1996; 24: 676-681.
23. Sidelmann UG, Cornett C, Tjørnelund J & Hansen SH. A comparative study of precision cut liver slices, hepatocytes, and liver microsomes from the Wistar rat using metronidazole as a model substance. Xenobiotica 1996; 26: 709-722.
24. Lake BG, Charzat C, Tredger JM, Renwick AB, Beamand JA & Price RJ. Induction of cytochrome P450 isoenzymes in cultured precision-cut rat and human liver slices. Xenobiotica 1996; 26: 297-306.
25. Brendel K, Gandolfi AJ, Krumdieck C & Smith PF. Tissue slicing and culturing revisited. TiPS 1987; 8: 11-15.
26. 3 antagonist tropisetron in liver and kidney slices of human, rat and dog with a comparison to in vivo. Eur. J. Drug Metab. Pharmacokinet. 1996; 21: 43-50.
27. Ekins E. Short-term maintenance of phase I and phase II metabolism in precision cut liver slices in dynamic organ culture. Drug Metab. Dispos. 1996; 24: 364-366.
28. Donato MT, Castell JV & Gómez-Lechón MJ. Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. Drug Metab. Dispos. 1995; 23: 553-558.
29. Ashforth EIL, Carlile DJ, Chenery R & Houston JB. Prediction of in vivo disposition of in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. J. Pharmacol. Exp. Ther. 1995; 274: 761-766.
30. Wrighton SA, Vandenbranden M, Stevens JC, Shipley LA & Ring BJ. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab. Rev. 1993; 25-4: 453-484.
31. Vickers AEM, Fisher V, Connors S, Fisher RL, Baldeck JP, Maurer G & Brendel K. Cyclosporin a metabolism in human liver, kidney, and intestine slices. Drug Metab. Dispos. 1992; 20: 802-809.
32. Gebhardt R, Wegner H & Alber J. Perifusion of co-cultured hepatocytes: optimization of studies on drug metabolism and cytotoxicity in vitro. Cell Biol. Toxicol. 1996; 12: 57-68.
33. Gonzalez FJ & Korzekwa KR. Cytochrome P450 expression systems. Annu. Rev. Pharmacol Toxicol. 1995; 35: 369-390.
34. Guengerich FP, Gillam WMJ, Ohmori S, Sandhu P, Brian WR, Sari MA & Iwasaki M. Expression of human cytochrome P450 enzymes in yeast and bacteria and relevance to studies on catalytic specificity. Toxicology 1993; 82: 21-37.
35. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS & Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor anti-depressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. J. Pharamacol. Exp. Ther. 1994; 268: 1278-1283.
36. Beaune P, Kremers P, Letawe-Goujon F & Gielen JE. Monoclonal antibodies against human liver cytochrome P450. Biochem. Pharmacol. 1985; 34: 3547-3552.
37. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Duan SX, Karsov D & Shader RI. Characterization of six in vitro reactions mediated by human cytochrome P450: Application to the testing of cytochrome P450 antibodies. Pharmacology 1996; 52: 125-134.
38. Gelboin HV, Krausz KW, Goldfarb I, Buters JTM, Yang SL, Gonzalez FJ, Korzekwa KR & Shou M. Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. Biochem. Pharmacol. 1995; 50: 1841-1850.
39. Lowry OH, Rosenbrough NJ, Farr AL & Randell RJ. Protein measurement with the folin reagent. J. Biol. Chem. 1951; 193: 265-275.
40. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976; 72: 248-254.
41. Vickers AEM, Connors S, Zollinger M, Biggi WA, Larrauri A, Vogelaar JPW & Brendel K. The biotransformation of the ergot derivate CQA 206-291 in human, dog and rat liver slice cultures and prediction of in vivo plasma clearance. Drug Metab. Dispos. 1993; 21: 454-459.
42. Ekins S, Murray GI, Burke MD, Williams A, Marchant NC & Hawksworth GM. Quantitative differences in phase I and II metabolism between rat precision cut liver slices and isolated hepatocytes. Drug Metab. Dispos. 1995; 23: 1274-1279.
43. Dogterom P. Development of a simple incubation system for metabolism studies with precision-cut liver slices. Drug Metab. Dispos. 1993; 21: 699-704.
44. Barr J, Weir AJ, Brendel K & Sipes IG. Liver slices in dynamic organ culture. II. An in vitro cellular technique for the study of integrated drug metabolism using human tissue. Xenobiotica 1991; 21: 341-350.
45. Hayes KA, Brennan B, Chenery R & Houston JB. In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data. Drug Metab. Dispos. 1995; 23: 349-353.
46. Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J & von Hoff D. A phase I trial of taxol given by a 6-hour intravenous infusion. J. Clin. Oncol. 1991; 9: 1261-1267.
47. Horwitz SB. Mechanism of action of taxol. TiPS 1992; 13: 134-135.
48. Rowinsky EK, Wright M, Monsarrat B, Lesser GJ & Donehower RC. Taxol: Pharmacology, metabolism and clinical implications. Cancer Surv. 1993; 17: 283-304.
49. Cresteil T, Monsarrat B, Alvinerie P, Tréluyer JM, Vieira I & Wright M. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isoenzyme involved in its biotransformation. Cancer Res. 1994; 54: 386-392.
50. Gelman K. Taxoids: paclitaxel and docetaxel. The Lancet 1994; 344: 1271.
51. Harris JW, Rahman A, Kim BR, Guengerich FP & Collins JM. Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 1994; 54: 4026-4035.
52. Kumar GK, Walle UK & Walle T. Cytochrome P450 3A-mediated human liver microsomal taxol 6α-hydrozulation. J. Pharmacol. Exp. Ther. 1994; 268: 1160-1165.
53. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ & Harris JW. Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 1994; 54: 5543-5546.
54. Anderson CD, Wang J, Kumar GN, McMillan JM, Walle UK & Walle T. Dexamethasone induction of taxol metabolism in the rat. Drug Metab. Dispos. 1995; 23: 1286-1290.
55. Jamis-Dow CA, Klecker RW, Katki AG & Collins JM. Metabolism of taxol by human and rat liver in vitro: A screen for drug interactions and interspecies differences. Cancer Chemother. Pharmacol. 1995; 36: 107-114.
56. Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo A, Steinberg SM, Goldspiel BR, Herdt J, O'Shaughnessy J, Balis FM & Chabner BA. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion. J. Clin. Oncol. 1994; 12: 1621-1629.
57. 3H) Taxol in the Sprague-Daley rat. Drug Metab. Dispos. ????; 22: 254-258.
58. Van den Berg JJA et al. Woordenboek oncologie. Zeist, Benecke Consultants, Glaxo B.V., pp. 94-103.
59. Woerdenbag HJ. Totaalsynthese van paclitaxel. PW 1994; 129: 347.
60. Kaye SB. Taxoids. Eur. J. Cancer 1995; 31A: 824-826.
61. Ringel I & Horwitz S. Studies with RP56976 (Taxotere): A semisynthetic analogue of taxol. J. Natl. Cancer Inst. 1991; 83: 288-291.
62. Royer I, Monsarrat B, Sonnier M, Wright M & Cresteil T. Metabolism of docetaxel by human cytochromes P450: Interactions with paclitaxel and other antineoplastic drugs. Cancer Res. 1996; 56: 58-65.
63. Bruno R & Sanderink GJ. Pharmacokinetics and metabolism of taxotere™ (docetaxel). Cancer Surv. 1993; 17: 305-313.
64. Monegier B, Gaillard C, Sablé S & Vuilhorgene M. Structures of the major human metabolites of docetaxel (RP 56976-Taxotere®). Tetrahedron Lett. 1994; 35: 3715-3718.
65. Fulton B & Spencer CM. Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 1996; 51: 1075-1092.
66. Sparreboom A, van Tellingen O, Scheerenburg EJ, Boesen JJB, Huizing MT, Nooijen WJ, Versluis C & Beijnen JH. Isolation, purification of major docetaxel metabolites from human feces. Drug Metab. Dispos. 1996; 24: 655-658.
67. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M & Rahmani R. Hepatic biotransformation of docetaxel (Taxotere®) in vitro: Involvement of the CYP3A subfamily in humans. Cancer Res. 1996; 56: 1296-1302.
68. Stevenson D, Briggs RJ, Chapman DJ & de Vos D. Determination of tamoxifen and five metabolites in plasma. J. Pharm. Biomed. Anal. 1988; 6: 1065-1068.
69. Jacolot F, Simon I, Dreano Y, Beaune P, Riche C & Berthou F. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol. 1991; 41: 1911-1919.
70. Jordan VC. Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res. Treat. 1982; 2: 123-138.
71. Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A & Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P450 catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 1993; 21: 645-656.
72. White INH, Davies A, Smith LL, Dawson S & de Matteis F. Induction of CYP2B1 and 3A1, and associated monooxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice. Biochem. Pharmacol. 1993; 45: 21-30.
73. Mani C, Pearce R, Parkinson A & Kupfer D. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis 1994; 15: 2715-2720.
74. 14C) Tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem. Pharmacol. 1995; 49: 1035-1042.
75. Daniels L, Blankson EA, Henderson CJ, Harris H, Wolf CR, Lennard MS & Tucker GT. Delineation of human cytochromes P450 involved in the metabolism of tamoxifen. Proceedings BPS. 1992; 153P, 8-10 April.
76. Kemp JV, Adam HK, Wakeling AE & Slater R. Identification and biological activity of tamoxifen metabolites in human serum. Biochem. Pharmacol. 1983; 32: 2045-2052.
77. Berthou F & Dréano Y. High-performance liquid Chromatographic analysis of tamoxifen, toremifene and their major human metabolites. J. Chromatogr. B. Biomed. Appl. 1993; 616: 117-127.
78. Carmichael PL, Ugwumadu AH, Neven P, Hewer AJ, Poon GK & Phillips DM. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res. 1996; 56: 1475-1479.
79. Blaschke G & Widey W. Metabolismus der enantiomere des zytostatikums ifosfamid. Arzneim. Forsch./Drug Res. 1989; 39-1: 223-226.
80. Boddy AV, Proctor M, Simmonds D, Lind MJ & Idle JR. Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. Eur. J. Cancer 1995; 31A: 69-76.
81. Murray M, Butler AM & Stupans I. Competitive inhibition of human liver microsomal cytochrome P450 3A-dependent steroid 6β-hydroxylation activity by cyclophosphamide and ifosfamide in vitro. /. Pharm. Exp. Ther. 1994; 270: 645-649.
82. Prasad VK, Corlett SA, Abaasi K, Heney D, Lewis I & Chrystyn H. Ifosfamide enantiomers: pharmacokinetics in children. Cancer Chemother. Pharmacol. 1994; 34: 447-449.
83. Wainer IW, Ducharme J & Granvil CP. The N-dechloroethylation of ifosfamide: Using stereochemistry to obtain an accurate picture of a clinically relevant metabolic pathway. Cancer Chemother. Pharmacol. 1996; 37: 332-336.
84. Wainer IW & Granvil CP. Stereoselective separations of chiral anticancer drugs and their application to pharmacodynamic and pharmacokinetic studies. Ther. Drug Monitor. 1993; 15: 570-575.
85. Lindemann H & Harbers E. In-vitro-reaktion der drei alkylierenden pharmaka cyclophosphamid, ifosfamid und trofosfamid mit DNS und DNS-bausteinen. Arzneim-Forsch./Drug Res. 1980; 30-2: 2075-2080.
86. Weber GF & Waxman DJ. Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes. Biochem. Pharmacol. 1993; 45: 1685-1694.
87. Chang TKH, Weber GF, Crespi CL & Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res. 1993; 53: 5629-5637.
88. Chen L & Waxman DL. Intramural activation and enhanced chemotherapeutic effect of oxazophosphorines following cytochrome P450 gene trasnfer. Development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 1995; 55: 581-589.
89. Norpoth K, Müller G & Raidt H. Isolierung und chacterisierung zweier hauptmetabolite von ifosfamid aus patientenurin. Arzneim.-Forsch./Drug Res. 1976; 26: 1376-1377.
90. Granville CP, Gehrcke B, König A & Wainer IW. Determination of the enantiomers of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in plasma and urine using enantioselective gas chromatography with mass spectrometric detection. J. Chramatogr. B Biomed. Appl. 1993; 622: 21-31.
91. Boos J, Küpker F, Blaschke G & Jürgens H. Trofosfamide metabolism in different species-ifosfamide is the predominant metabolite. Cancer Chemother. Pharmacol. 1993; 33: 71-76.